| |
Newsroom /
Health and Fitness
/
Healthcare
/
The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016
The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016
Psoriasis is a Strong Growing Market attributed with Increased Competition Coupled with Strong Pipeline
kent,
sidcup,
United Kingdom
(prbd.net)
29/03/2010
"The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016"
The global dermatology therapeutics market generated approximately $10,039m in 2009. The market is estimated to reach revenues of approximately $12,520m by 2016 growing at a CAGR of 3.2% between 2009 and 2016. In 2010, the market is forecast to reach revenues of about $10,354m. From 2001, the market grew at a CAGR of 2.3% to reach $10,039m in 2009. Psoriasis was one of the fastest growing segments. This growth is primarily attributed to increased competition among the existing products and also a strong pipeline with more emerging therapies. The current market is crowded with biologics and also topical treatments for psoriasis. The pipeline is also very strong with biologics as well as several other treatments for mild to moderate psoriasis. Hence the psoriasis market is expected to reap large revenues with the increased uptake of biologics, and the increased awareness of the disease in patients leading to increased treatment seeking rates at the early stages of the disease.
In the dermatology sector, most of the companies coordinate their R&D activities to constantly expand their product pipeline with innovative drugs. Though there is a consistent and continuous threat from generics and other alternatives, companies in the dermatology sector are not reluctant to invest in R&D and are focused on offering new products to the market. There are approximately more then 700 drugs in the dermatology pipeline.
In 2008 and 2009, the dermatology sector witnessed numerous licensing agreements. With about 25 drug licensing agreements, it is evident that the dermatology therapeutics sector is on an enormous growth path for novel therapeutics. The approval stages for the drug witnessed increasing numbers of licensing agreements. Geographically, emerging nations will foresee strong growth and hence the licensing agreements in these nations are expected to increase. In a way, licensing agreements strengthen the financial stability of new players in the market and expand the potential of the major players involved in the deal.
Most licensing agreements took place in dermatology indications such as dermatitis, psoriasis and general dermatology. All of these three combined accounted for a share of 60% of the licensing agreements. Multiple indications refers to agreements that took place across various dermatology indications. It accounted for a share of 30%. Licensing agreements for acne and rosacea were 9% and 1% respectively.
GBI Research has released its research, “The Future of Dermatology Therapeutics, Analysis and Market Forecasts to 2016 - Increasing Prescription Rate to Drive Revenues”. The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global dermatology therapeutics market. The report analyzes the markets for dermatology therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns and sales are forecast until 2016 for the key geographies as well as select therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
http://www.gbiresearch.com
About
GBI Research is a global market intelligence services company providing information research and analysis products and services.
|